ISS issued guidance today on its benchmark policy application in the context of COVID-19. The guidance - which demonstrates much-needed flexibility in lieu of strict application of a number of ISS benchmark policies - addresses meeting postponement and format; adoption of poison pills; director attendance; policies implicated by changes in board and senior management composition; compensation-related changes/actions (e.g., changes in metrics, goals, targets; stock option repricings); and capital structure/management including reductions or suspensions in dividend payments, stock buybacks and capital-raising activities.
See ISS's release, and these relevant US benchmark policy documents:
Glass Lewis issued its COVID-19 policy application approach late last month, which we reported on here.
Access these and additional resources on our Proxy Advisors page.